Arnold L. Oronsky, Ph.D., Joins Sera’s Board of Directors
SALT LAKE CITY, February 24, 2015–Sera Prognostics, Inc., a women’s healthcare company, today announced that Arnold L. Oronsky, Ph.D., General Partner at InterWest Partners, LLC, was appointed to its Board of Directors. Dr. Oronsky’s addition to the Sera board occurs as the company is in the final stages of developing PreTRM™, its novel proteomic predictor for preterm birth risk, prior to its commercial launch.
“Dr. Oronsky is accomplished as a business leader and investor in innovative medical technologies. We are very pleased that he has joined Sera’s Board,” said Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer of Sera Prognostics. “Arnie’s broad experience has particular relevance for Sera at this time, as we complete the development of our PreTRM™ test. His acknowledged success as a strategic thinker further adds to the depth of our board as we transition Sera from research and development into a revenue stage company.”
As General Partner leading healthcare investments at InterWest Partners, Dr. Oronsky has significant experience investing in diagnostic and pharmaceutical companies. He has served on numerous boards of successful healthcare companies that address significant unmet medical needs through innovative technologies. Prior to joining InterWest Partners in 1994, Dr. Oronsky led pharmaceutical research as vice president for discovery research of the Lederle Laboratories division of American Cyanamid Company. He earned a Ph.D. in immunology from Columbia University and is currently a senior lecturer at the Department of Medicine at Johns Hopkins Medical School.
“Sera’s strategy employs cutting-edge diagnostic science to address some of the biggest problems in maternal fetal medicine worldwide,” commented Dr. Oronsky. “I am pleased to work with Sera’s exceptional team to realize the promise of its technology and transform the company into a commercial business that creates lasting value and makes an important difference in the lives of patients and families globally.”
Sera today also announced that Douglas Fisher, M.D., has recently resigned his position as a director on Sera’s Board to join the company’s management team as Chief Business Officer.
“I thank Doug Fisher for his conscientious service on our Board and now look forward to working closely with him as our Chief Business Officer as we further develop and execute the company’s strategy to become a global leader in maternal fetal medicine,” said Critchfield.
Dr. Fisher has been a partner at InterWest Partners, serving on Sera’s Board of Directors since November 2011. He received his M.D. and M.B.A. from the School of Medicine and the Wharton School, respectively, at the University of Pennsylvania. Dr. Fisher has focused on biopharmaceutical, diagnostic and medical device investments throughout his career, working in venture capital, consulting and pharmaceutical industries.
“It has been a privilege to be involved with the Company since its Series A funding in 2011 and to serve on Sera’s Board,” said Dr. Fisher. “I have tremendous confidence in the approach that our team is diligently pursuing to develop its first-to-market proteomic PreTRM™ test that has high potential to significantly impact pregnancy care. I look forward to contributing further to Sera’s success as its business and strategy development executive.”
About Sera Prognostics, Inc.
Sera Prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth risk and other pregnancy complications. Sera’s tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. The company has assembled a strong management team and Board of Directors with significant clinical development and women’s healthcare diagnostic experience. Sera has conducted the Proteomic Assessment of Preterm Risk (PAPR) study, one of the world’s largest and broadest clinical trials to validate the performance of the Company’s PreTRM™ test. PAPR enrolled 5,501 patients from 11 centers across the United States, representing the diversity of the intended use population for asymptomatic singleton pregnancies. The Company is supported by a strong group of investors, including The Bill and Melinda Gates Foundation, Chione, Ltd, Domain Associates, InterWest Partners, Catalyst Health Ventures, UpStart Life Sciences Capital, and Osage University Partners. The Company is working with the Bill and Melinda Gates Foundation to translate its discoveries and develop technologies to benefit women and infants in underserved countries worldwide. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company’s website at www.seraprognostics.com.
Andrew Sauter, CFO
Sera Prognostics, Inc.
MediaContact for Sera Prognostics:
Continuum Health Communications